873054-75-2 Usage
General Description
The chemical "[5-[(4-oxo-1H-quinolin-3-yl)carbonylamino]-2-tert-butylphenyl]methylaminoformic acid tert-butyl ester" is a complex compound with a molecular formula of C28H32N4O5. It consists of a quinoline ring, a carbonylamino group, a tert-butylphenyl group, a methylaminoformic acid group, and a tert-butyl ester group. [5-[(4-oxo-1H-quinolin-3-yl)carbonylamino]-2-tert-butylphenyl]methylaminoformic acid tert-butyl ester is a synthetic organic molecule that may have potential applications in medicinal chemistry, drug development, or other research fields. Its specific properties and potential uses would need to be determined through further experimentation and analysis.
Check Digit Verification of cas no
The CAS Registry Mumber 873054-75-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,7,3,0,5 and 4 respectively; the second part has 2 digits, 7 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 873054-75:
(8*8)+(7*7)+(6*3)+(5*0)+(4*5)+(3*4)+(2*7)+(1*5)=182
182 % 10 = 2
So 873054-75-2 is a valid CAS Registry Number.
873054-75-2Relevant articles and documents
Discovery of N -(2,4-Di- tert -butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (VX-770, Ivacaftor), a potent and orally bioavailable CFTR potentiator
Hadida, Sabine,Van Goor, Fredrick,Zhou, Jinglan,Arumugam, Vijayalaksmi,McCartney, Jason,Hazlewood, Anna,Decker, Caroline,Negulescu, Paul,Grootenhuis, Peter D. J.
, p. 9776 - 9795 (2015/01/16)
Quinolinone-3-carboxamide 1, a novel CFTR potentiator, was discovered using high-throughput screening in NIH-3T3 cells expressing the F508del-CFTR mutation. Extensive medicinal chemistry and iterative structure-activity relationship (SAR) studies to evaluate potency, selectivity, and pharmacokinetic properties resulted in the identification of N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (VX-770, 48, ivacaftor), an investigational drug candidate approved by the FDA for the treatment of CF patients 6 years of age and older carrying the G551D mutation.
